Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al

Affiliations

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
² Institute of Rheumatology, Prague, Czech Republic.
³ Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.

Free article

Comment

Paul Emery et al. Ann Rheum Dis. 2016 Jul.

Free article

. 2016 Jul;75(7):e38.

doi: 10.1136/annrheumdis-2016-209517. Epub 2016 May 4.

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
² Institute of Rheumatology, Prague, Czech Republic.
³ Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.

No abstract available

Keywords: Disease Activity; Rheumatoid Arthritis; Treatment.

Comment on

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J. Emery P, et al. Ann Rheum Dis. 2017 Jan;76(1):51-57. doi: 10.1136/annrheumdis-2015-207588. Epub 2015 Jul 6. Ann Rheum Dis. 2017. PMID: 26150601 Free PMC article. Clinical Trial.
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration.
Marshall L, Hickling T, Bill D, Mahgoub E. Marshall L, et al. Ann Rheum Dis. 2016 Jul;75(7):e37. doi: 10.1136/annrheumdis-2016-209502. Epub 2016 Mar 31. Ann Rheum Dis. 2016. PMID: 27034452 No abstract available.